To print: Select File and then Print from your browser's menu

Title: Chemotherapy Drug Shrinks Brain Tumors

"Chemotherapy Drug Shrinks Brain Tumors"

ST. PAUL, MN -- May 21, 2007 -- Cancerous brain tumors appear to respond favorably to the drug temozolomide when used as primary chemotherapy after surgery, and the treatment appears to work best in people missing a certain gene, according to a study published in the May 22, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology. Researchers studied 149 people with low grade gliomas, a slow-growing type of brain tumor, who were treated with temozolomide chemotherapy for up to 30 months. The study found temozolomide reduced the size of brain tumors in 53% of the study's participants and stabilized the size of brain tumors in 37% of the study's participants. However, in 10% of the group, the size of the brain tumors increased by more than 25%. Genetic testing was also performed in 86 of the participants. In 42% of the participants, the gene 1p/19q was missing. Those missing the gene were more likely to respond well to the drug. They also had more months without the tumor developing than those with the gene and were less likely to die during the study. "Our findings are consistent with previous smaller studies showing temozolomide as a primary treatment is effective and tolerable, and an added benefit is the discovery that the loss of chromosome 1p/19q predicts how well a person is going to respond to the treatment," said study author Khe Hoang-Xuan, MD, PhD, with the Pitie-Salpetriere Hospital in Paris, France. However, Hoang-Xuan says comparing temozolomide to radiotherapy, which is the standard treatment for such brain tumors, isn't easy and he says that's why continued research into comparing the two treatments is needed. SOURCE: The American Academy of Neurology

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.